Icosavax, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
1930 Boren Ave., Suite 1000, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.67K % -22.3%
Debt-to-equity 8.94 % +45.1%
Return On Equity -43.1 % -25.4%
Return On Assets -39.5 % -22.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.1M shares +25.5%
Common Stock, Shares, Outstanding 50.1M shares +25.9%
Entity Public Float 184M USD
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 50M shares +25.9%
Weighted Average Number of Shares Outstanding, Diluted 50M shares +25.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 70M USD +10.7%
General and Administrative Expense 35.8M USD +30.3%
Operating Income (Loss) -106M USD -20.1%
Nonoperating Income (Expense) 9.17M USD +406%
Net Income (Loss) Attributable to Parent -96.7M USD -12%
Earnings Per Share, Basic -2.22 USD/shares +20%
Earnings Per Share, Diluted -2.22 USD/shares +20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments 229M USD
Assets, Current 235M USD +2.88%
Property, Plant and Equipment, Net 11.4M USD -3.51%
Operating Lease, Right-of-Use Asset 2.98M USD -10.7%
Other Assets, Noncurrent 1.61M USD
Assets 251M USD +3.04%
Accrued Liabilities, Current 9.61M USD +42.9%
Liabilities, Current 13M USD -0.02%
Operating Lease, Liability, Noncurrent 5.89M USD +15.7%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 18.9M USD +3.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax -48K USD +92.1%
Retained Earnings (Accumulated Deficit) -259M USD -59.6%
Stockholders' Equity Attributable to Parent 232M USD +2.98%
Liabilities and Equity 251M USD +3.04%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.6M USD -24%
Net Cash Provided by (Used in) Financing Activities 117K USD -57.6%
Net Cash Provided by (Used in) Investing Activities 12M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 50.1M shares +25.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 63.2M USD -3.55%
Deferred Tax Assets, Valuation Allowance 36.4M USD +77.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 38.5M USD +84.9%
Operating Lease, Liability 8.07M USD +20.8%
Depreciation 643K USD +1395%
Payments to Acquire Property, Plant, and Equipment 1.57M USD +40.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -96.2M USD +1.29%
Property, Plant and Equipment, Gross 12.5M USD +975%
Operating Lease, Liability, Current 2.19M USD +37.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.2M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 365K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.57M USD -15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.27M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 17.3M USD +37.1%
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 1.55M USD +104%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.34M USD +3%
Additional Paid in Capital 491M USD +26.5%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 25.1M USD +30.5%
Interest Expense 263K USD